Industry News
Pharmaceutical Industry News
Pfizer has unveiled phase 3…
Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its competition with Sanofi’s Qfitlia and Novo Nordisk’s Alhemo.
After a record-setting October…
After a record-setting October that easily dwarfed all preceding months in the year, TV drug ad spending found a happy medium in November.
With FDA approval to treat…
With FDA approval to treat marginal zone lymphoma, Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five different types
On “The Top Line,” EY’s Arda…
On “The Top Line,” EY’s Arda Ural talks with Fierce Pharma about biopharma dealmaking trends, valuation shifts and what the industry should expect in 2026.
Halozyme is seeing some progress…
Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & Co.'s new version of Keytruda. A court in Germany ordered the pharma giant to halt Keytruda
The FDA is investigating a safety…
The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to enter the crowded IgA nephropathy field. Daiichi Sankyo won reversal of an unfavorable ruling in
Avalere Health has hired Sarah…
Avalere Health has hired Sarah Hall as president of U.S. marketing, tapping the direct-to-consumer expert to lead its team through a “politically dynamic” period.
Retail pharmacy data insights…
Retail pharmacy data insights uncover patient barriers, helping drugmakers improve access, boost adherence and drive better outcomes.
A trio of drugmakers are treading…
A trio of drugmakers are treading the boards to raise awareness of global antimicrobial resistance.
Regeneron is taking a simplified…
Regeneron is taking a simplified approach in its bid to move T-cell engagers Lynozyfic and Ordspono into earlier lines of blood cancer treatment by trying to offer less onerous regimens for patients.
The latest untitled letter from…
The latest untitled letter from the FDA’s Office of Prescription Drug Promotion zeroes in on a patient testimonial video about Daiichi Sankyo’s tenosynovial giant cell tumor treatment Turalio.
Theresa Michele, the director of…
Theresa Michele, the director of the Office of Nonprescription Drugs for a decade, has been transferred to another agency role, Fierce Pharma has learned.
Drastic overhauls of U.S. vaccine…
Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from 12 former commissioners of the agency.
The Buckland Group launched Quvara…
The Buckland Group launched Quvara Medical as the newest CDMO to debut this year after buying a former Becton Dickinson manufacturing site in the U.K. for an undisclosed price.
China biopharma contracting…
China biopharma contracting juggernaut WuXi AppTec faces a new threat that its extensive business ties to the U.S. could be imperiled as the Pentagon has identified the company as one of eight that assist the
Former F.D.A. Commissioners Sound Alarm on Plan to Change Vaccine Policy
Twelve former commissioners, in a New England Journal of Medicine article, said they were “deeply concerned” by a leaked memo from the agency’s vaccine regulator.
The non-covalent BTK inhibitor can…
The non-covalent BTK inhibitor can now be used as an earlier treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Learn how a company’s focus on…
Learn how a company’s focus on understanding the patient journey is making healthcare more intuitive and equitable across the spectrum of medicine.
Cosmo Pharmaceuticals has revealed…
Cosmo Pharmaceuticals has revealed topline results from two phase 3 trials which indicate that its topical cream clascoterone could become a game-changing treatment for male-pattern hair loss.
A federal appeals court has…
A federal appeals court has overturned a previous ruling out of Texas that required Daiichi to pay $41.8 million in Enhertu royalties, plus an 8% running royalty rate, to its former ADC partner, Seagen.